Literature DB >> 8887489

Dengue 1 virus binding to human hepatoma HepG2 and simian Vero cell surfaces differs.

P Marianneau1, F Mégret, R Olivier, D M Morens, V Deubel.   

Abstract

We analysed the binding and infectivity of dengue virus serotype 1 (DEN-1) for the human hepatoma cell line HepG2 in comparison with the simian kidney cell line Vero. The higher susceptibility of Vero cells to DEN-1 correlated with greater binding affinity of DEN-1 to these cells. In contrast, the capacity of virus attachment was higher for HepG2 than for Vero cells. Profiles of DEN-1 binding at different pH were markedly different between the two cell types. A type-specific neutralizing monoclonal antibody reduced initial virus binding to both cell types similarly but complex- and group-specific neutralizing antibodies affected virus adhesion differently. Altogether, these results suggest the involvement of different receptors or receptors presented in a different environment on the cell surface in the two cell lines. The sensitivity to proteolytic enzymes and to ionic detergent of the binding sites on the two cell types was tested and results indicated that they may be multimeric proteins or protein complexes.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8887489     DOI: 10.1099/0022-1317-77-10-2547

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  16 in total

1.  Infection of human cells by dengue virus is modulated by different cell types and viral strains.

Authors:  M S Diamond; D Edgil; T G Roberts; B Lu; E Harris
Journal:  J Virol       Date:  2000-09       Impact factor: 5.103

2.  Identification of two surface proteins from C6/36 cells that bind dengue type 4 virus.

Authors:  J S Salas-Benito; R M del Angel
Journal:  J Virol       Date:  1997-10       Impact factor: 5.103

3.  Chemical mutagenesis of dengue virus type 4 yields mutant viruses which are temperature sensitive in vero cells or human liver cells and attenuated in mice.

Authors:  J E Blaney; D H Johnson; C Y Firestone; C T Hanson; B R Murphy; S S Whitehead
Journal:  J Virol       Date:  2001-10       Impact factor: 5.103

4.  Dengue virus replication in human hepatoma cells activates NF-kappaB which in turn induces apoptotic cell death.

Authors:  P Marianneau; A Cardona; L Edelman; V Deubel; P Desprès
Journal:  J Virol       Date:  1997-04       Impact factor: 5.103

5.  Infection of primary cultures of human Kupffer cells by Dengue virus: no viral progeny synthesis, but cytokine production is evident.

Authors:  P Marianneau; A M Steffan; C Royer; M T Drouet; D Jaeck; A Kirn; V Deubel
Journal:  J Virol       Date:  1999-06       Impact factor: 5.103

6.  Identification of a putative coreceptor on Vero cells that participates in dengue 4 virus infection.

Authors:  J J Martínez-Barragán; R M del Angel
Journal:  J Virol       Date:  2001-09       Impact factor: 5.103

7.  Serotype-specific entry of dengue virus into liver cells: identification of the 37-kilodalton/67-kilodalton high-affinity laminin receptor as a dengue virus serotype 1 receptor.

Authors:  Chutima Thepparit; Duncan R Smith
Journal:  J Virol       Date:  2004-11       Impact factor: 5.103

8.  An external loop region of domain III of dengue virus type 2 envelope protein is involved in serotype-specific binding to mosquito but not mammalian cells.

Authors:  Jan-Jong Hung; Meng-Ti Hsieh; Ming-Jer Young; Chuan-Liang Kao; Chwan-Chuen King; Wen Chang
Journal:  J Virol       Date:  2004-01       Impact factor: 5.103

9.  Identification of cellular proteome modifications in response to West Nile virus infection.

Authors:  Boris Pastorino; Elodie Boucomont-Chapeaublanc; Christophe N Peyrefitte; Maya Belghazi; Thierry Fusaï; Christophe Rogier; Hugues J Tolou; Lionel Almeras
Journal:  Mol Cell Proteomics       Date:  2009-04-24       Impact factor: 5.911

10.  Molecular mechanism of pathogenesis of dengue virus: Entry and fusion with target cell.

Authors:  S K Jain
Journal:  Indian J Clin Biochem       Date:  2005-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.